Search

RAGE Antibodies Patent Granted SUNY Apr 14

USPTO granted Patent US12600778B2 to The Research Foundation for The State University of New York for antibodies specific to the heparan sulfate binding site of Receptor for Advanced Glycation Endproducts (RAGE). The patent includes methods for treating conditions involving RAGE through antibody administration, with 4 claims allowed.

Novo Nordisk Patent for IL-6 Antagonist Treatment of Diuretic Resistant Heart Failure

The USPTO granted Patent US12600773B2 to Novo Nordisk A/S on April 14, 2026, covering methods of treating diuretic resistant heart failure patients carrying at least one copy of the TMPRSS6 rs855791 allele by administering an IL-6 antagonist. The patent also covers treatment of patients with elevated urine or plasma IL-6 levels requiring diuresis. The patent (CPC: C07K 16/248) names five inventors and issues from Application No. 17519082 filed November 4, 2021, with 10 claims granted.

Hoffmann-La Roche Granted Amino-Pyrimidine Amide Patent US12600712B2

USPTO granted Patent US12600712B2 to Hoffmann-La Roche Inc. on April 14, 2026, covering amino-pyrimidine amide compounds with general formula (I) and methods of using such compounds. The patent includes 11 claims and CPC classifications C07D 403/06 and C07D 491/107 in organic chemistry. The filing date was December 7, 2022, with Application No. 18062644.

Gannex Pharma FXR Modulating Compound Patent US12600716B2

USPTO granted patent US12600716B2 to Gannex Pharma Co. Ltd. on April 14, 2026, for FXR-modulating compounds having a structure of formula (I), including pharmaceutically acceptable salts, esters, and stereoisomers. The patent contains 19 claims and covers therapeutic applications including liver disease (A61P 1/16), metabolic disorders, cardiovascular conditions, and kidney disease.

Hutchmed Crystalline Forms Patent Grant US12600713B2

USPTO granted patent US12600713B2 to Hutchmed Limited on April 14, 2026 for crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide, a pharmaceutical compound. Inventors are Zhenping Wu, Wenji Li, and Yuping Chu. The patent contains 28 claims and was filed on February 27, 2024.

Boehringer Ingelheim Patent for sGC Activators in Systemic Sclerosis Treatment

The USPTO granted patent US12600715B2 to Boehringer Ingelheim International GmbH covering methods for treating systemic sclerosis using soluble guanylate cyclase (sGC) activators of formula (I) or their pharmaceutically acceptable salts. The patent names Mary Ruth Flack, Julia Kaufman, and Indra Sethy-Coraci as inventors and includes 20 claims spanning therapeutic applications including respiratory, dermatological, pain, and immunological indications. This method patent provides Boehringer Ingelheim with enforceable exclusivity over the specified sGC activator treatment protocol for systemic sclerosis in the United States.

Nonpeptide Somatostatin Type 5 Receptor Agonists and Uses Thereof

USPTO granted patent US12600709B2 to Crinetics Pharmaceuticals covering nonpeptide somatostatin type 5 receptor agonists, methods of making the compounds, pharmaceutical compositions, and methods of using the compounds in treating conditions that benefit from somatostatin modulation. The patent includes 4 claims.

Cannabinoid Derivatives, Precursors and Uses - Patent US12600707B2

USPTO granted patent US12600707B2 to Kare Chemical Technologies Inc. on April 14, 2026, covering new cannabinoid derivatives, precursors, and processes for their preparation. The patent also claims pharmaceutical and analytical uses of these compounds. The patent (10 claims) protects the invention until 2040 based on the September 2020 filing date.

US12600703B2 - Farnesyl Dibenzodiazepinone Synthesis Patent

USPTO granted patent US12600703B2 to AMO Pharma Ltd. covering methods of synthesizing farnesyl dibenzodiazepinone compounds, including AMO-01. The patent has 4 claims and was filed on May 28, 2021. Patent grants establish legally enforceable intellectual property rights for the disclosed chemical synthesis methods.

University of Pittsburgh Heat Shock Protein Modulator Patent for Huntington Disease

USPTO granted patent US12600705B2 to University of Pittsburgh for thiadiazine compounds as heat shock protein modulators. The patent covers therapeutic applications for Huntington disease, other neurodegenerative disorders, and cancer. The patent includes 13 claims.